Search results
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Accelerate therapeutic discovery and maximize ROI with our streamlined platform, fully integrated across your entire portfolio. Use digital and decentralized trials to scale your pipeline beyond what's possible with traditional clinical trials.
Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.
Join leading clinical experts as they discuss and debunk the top 5 myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter, faster decisions.
Gain a quick overview of what top trends and topics dominated DIA 2023.
With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.
A top 10 pharmaceutical company looked to Medable to streamline participant burden and enhance site and team experience in oncology trials, while establishing a scalable template for future trials in oncology and other areas.
Discover how Medable helped digitize and standardize a client's participant pain body maps for a diabetic polyneuropathy trial.
When OpenAI unveiled ChatGPT in November 2022, it ignited unprecedented interest in artificial intelligence. Three years later, generative AI and machine learning have caused seismic shifts in industries worldwide. The pharmaceutical industry is not left out of this shift, with Roots Analysis reporting that they expect AI within clinical trials to grow at a compound annual growth rate of 16% through 2035. This growth is driven by belief in AI’s unique ability to process and analyze massive datasets at groundbreaking speeds, identifying patterns and generating insights that would be impossible to discover through traditional methods. By leveraging these capabilities, pharmaceutical companies hope to fundamentally reimagine core aspects of clinical trials, from initial design through final data analysis.
During a on-demand demo, watch how Medable Studio and AI removes your manual workload to rapidly deliver assessment screens of varying complexity and logic, ultimately accelerating your path to FPI.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Initially perceived as a groundbreaking departure, DCTs have transformed from a disruptive force challenging the norm to an integral concept, now widely embraced in the clinical trial landscape. Join us for this upcoming Clinical Leader Live session, where experts will explore the current landscape, highlighting the positive impact of DCTs and their transition from innovation to indispensable practice in the era of evidence generation and modern clinical trials.
Read this white paper to learn how eConsent's flexibility helps you educate and retain patients worldwide, regardless of signature requirements, and how to implement it across your organization.
Experts from Medable, Syneos, and Pluto Health discuss how they have partnered to deploy patient-first digital trial solutions that leverage RWD, transforming it into actionable RWE insights for a sponsor client.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Learn why it's important to comment on the recent ICH E6(R3) in order to ensure better regulation for modern clinical trials.
Learn how we handle connected device shipping for our customers' clinical trials, achieving a market-leading 99% connected device shipment rate.
Check out the news, trends, and insights from this year's SCOPE 2024 conference.
See why the electronic clinical outcome (eCOA) market is poised to continue its rapid growth and why Medable customers have chosen eCOA as a future foundation for their next era of clinical conduct.
See why many of the top pharma are focused on building the "next model" of clinical trial conduct using foundational platforms.
Medable's Site Success department, created to prevent technological challenges from impacting clinical trials, includes a team of specialists led by Annie Hesslewood. The team engages with CROs, supports site-level adoption, and works with the Medable product team to enhance user experience, with the goal of making technological adoption seamless and forgettable.
Learn how Medable's eCOA (electronic clinical outcome assessment) solution was able to deliver >90% adherence and scalability for a top pharmaceutical weight management clinical trial.
When talking to customers conducting their first multi-country trial, we sometimes liken clinical trials to spider webs. Just as a garden spider’s web differs from a black widow’s, clinical trials follow unique patterns in every region. Each country comes with its own set of rules, ethical standards, approval processes, and data privacy laws. Cultural factors also play a crucial role in how patients are recruited and understand Clinical trials, requiring sensitive communication and a deep respect for participants’ needs.In Japan, these regulatory and cultural intricacies form a complex ‘web,’ with anchor points and structural requirements that, when understood and implemented correctly, create a framework for success. However, conducting Clinical trials in Japan has historically posed challenges for Sponsors and Contract Research Organizations (CROs). When we first entered the region, one Sponsor consistently cited issues with eCOA solutions and site and patient support, not fully adapting to Japan’s unique requirements. This feedback, combined with our own experiences on the ground, revealed a clear need for improvement.Today, we can proudly say that the solutions we put in place have transformed Japan’s Clinical trial landscape, and what was once a challenge has now become the “gold standard” for supporting Clinical trials in the region.
Contact Medable for a demo and to learn more about DCT certification, careers, and support. Medable, per Everest Group Peak matrix, is the top decentralized clinical trial company.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Explore the transformative impact of eCOA and wearables in oncology clinical trials. Learn how these technologies enhance data collection, patient engagement, and real-time monitoring to improve trial outcomes.
Explore practical strategies for ensuring data quality in eCOA clinical trials, covering platform design, patient engagement, data validation, and regulatory adherence.
See how customers have had success with Medable, our trial platform, and our teams.
Streamline your clinical trial and generate high-quality data with a #1 rated, easy-to-use platform, offered in over 60 countries and 120 languages. Book a demo to learn more.
Learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.
Join Medable's Mohammed Ali, Chief Domain Expert and Shubha Govil, SVP of Product Management,Platform to hear how top pharma teams have adopted digital technology across a platform to reduce costs and accelerate time to market.
Medable worked with a top 5 pharma company to increase the safety of patients as anti-cancer treatments may cause pulmonary toxicity, ranging from asymptomatic radiological changes to respiratory failure, and is considered a common side effect.
In this webinar, learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.
Learn how we can help you navigate the complexities of clinical operations so that you can meet your study's milestones faster and easier.
In January 2024, panelists from Syneos, Obvious Ventures, Sapphire Ventures, IDEA Pharma, and GSR Ventures joined Medable’s CEO, Dr. Michelle Longmire, to discuss the purpose, potential, and power that artificial intelligence (AI) technology offers clinical trials. Here's what they had to say.
A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan. Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable to develop an initiative to enhance the region’s patient and site experience.
See how Medable helped one customer achieve their fastest enrollment ever.
The partnership between Medable, U.S. Renal Care, and the top ten pharmaceutical sponsor exemplifies the transformative power of Medable’s Total Consent solution in clinical trials. By overcoming common misconceptions around participant age, cost, and complexity, Medable’s platform proved to be a flexible, fast, and efficient solution for the elderly renal care population. U.S. Renal Care sought to use Medable’s Total Consent (Medable’s eConsent solution) for an investigator-initiated trial. The phase 4 trial, which was funded by a top 10 pharmaceutical company, sought to enroll elderly participants suffering from Anemia ESKD (End Stage Kidney Disease) across 476 site users. The trial would be managed by three central principal investigators (PIs).
A top, global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality.
A top-10 global pharmaceutical company came to Medable looking to standardize and scale their weight management trials. The trial was driven by a master protocol with multiple sub-studies across 70+ research sites. The partner was concerned about the participant and site experience, particularly participant enrollment and study startup timelines, as the trial required participants to enroll through the master protocol before enrolling into a sub-study. Read ahead to see how Medable accomplished this and more.